Covid: What do we know about the Omicron variant and should we be worried?

Omicron COVID-19 Variant: Cases Detected in the United Kingdom as International Concern Grows

The emergence of the Omicron variant of SARS-CoV-2 in late November 2021 raised significant concerns among public health authorities worldwide. After its identification in southern Africa, several countries began reporting cases, prompting governments to introduce new travel restrictions and strengthen measures aimed at limiting the spread of the virus.

In the United Kingdom, three cases of the Omicron variant had been detected by the end of November 2021. The UK Health Security Agency (UKHSA) confirmed the latest case on Sunday, reporting that the individual had tested positive after arriving in the country following travel connected to southern Africa. 

The identification of these cases highlighted the importance of genomic surveillance, international cooperation, and rapid public health responses in monitoring emerging variants of concern.

Three Omicron Cases Identified in the United Kingdom

According to the UK Health Security Agency, the latest confirmed case involved an individual who had recently travelled to the United Kingdom from southern Africa. During the person's stay, they had been in Westminster, in central London, but were no longer in the country when the case was announced.

The two previously identified cases were reported in Brentwood, Essex, and Nottingham, as confirmed by then Health Secretary Sajid Javid. Authorities indicated that these two infections were linked to each other and were also associated with travel to southern Africa.

The identification of cases in different parts of the country led health officials to investigate possible exposure routes and identify individuals who may have come into contact with infected travellers. Such investigations are an important part of outbreak management because they help authorities assess whether infections are limited to imported cases or whether community transmission may already be occurring.

The UKHSA continued to monitor the situation and worked with public health teams to support testing, contact tracing, and genomic analysis.

New COVID-19 Measures Announced by the UK Government

Following the identification of the first Omicron cases, Prime Minister Boris Johnson announced a series of measures intended to reduce the risk of further transmission in the United Kingdom.

The response included strengthened precautions and changes to travel-related requirements. These measures were introduced as scientists and public health authorities sought to understand the characteristics of the newly identified variant.

The government's approach reflected concerns that international travel could contribute to the rapid movement of the variant between countries. Additional screening, testing, and isolation measures were considered important tools for identifying infections early and limiting onward transmission.

The announcements also generated public discussion about the potential impact of renewed restrictions on daily activities, businesses, and plans for the Christmas holiday period.

At the time, many people were concerned about whether the new measures would be sufficient to prevent another significant wave of infections. However, the effectiveness of these interventions depended on several factors, including the transmissibility of Omicron, population immunity, compliance with public health recommendations, and the speed at which cases could be detected.

Coronavirus Disease (COVID-19): A primer for emergency physicians -  ScienceDirect

Why Did Omicron Become a Variant of Concern?

The World Health Organization (WHO) designated Omicron as a Variant of Concern in November 2021. This classification reflected the presence of a substantial number of genetic mutations and the possibility that some of these changes could influence the virus's epidemiological behaviour.

SARS-CoV-2, the virus responsible for COVID-19, continuously undergoes genetic changes as it replicates and spreads. Most mutations do not necessarily produce significant changes in viral behaviour. However, combinations of mutations can sometimes affect characteristics such as transmissibility, disease severity, or the ability of the virus to partially evade immune protection.

Omicron attracted particular attention because of the large number of mutations identified in its spike protein. This protein plays a central role in viral entry into human cells and is also a major target of the immune response generated by many COVID-19 vaccines.

Scientists therefore raised questions about whether the mutations could influence the effectiveness of existing vaccines or increase the likelihood of reinfection.

Nevertheless, at the time of its initial identification, the full clinical and epidemiological implications of these mutations had not yet been established. Researchers emphasized the need for additional laboratory studies and epidemiological investigations before drawing definitive conclusions.

In Which Countries Had the Omicron Variant Been Detected?

The first known identification of the Omicron variant was reported in Botswana, where samples collected on 11 November 2021 were subsequently analysed. South Africa formally notified the WHO about the variant on 24 November 2021 after genomic surveillance identified the new genetic profile.

Within a short period, additional countries began reporting suspected or confirmed infections.

By the end of November 2021, cases had been identified or reported in several locations, including:

  • Botswana: Among the first countries where the variant was identified.

  • South Africa: The country that formally reported the variant to the WHO and detected cases through genomic surveillance.

  • United Kingdom: Three cases were reported during the initial period described in this article.

  • Belgium: Reported one of the first confirmed cases in Europe.

  • Hong Kong: Identified infections associated with international travel, including a traveller returning from South Africa.

  • Israel: Reported a confirmed case linked to international travel.

  • Australia: Detected two cases among travellers arriving from southern Africa.

  • Italy and Germany: Reported cases as European surveillance activities expanded.

  • Netherlands: Detected Omicron infections among travellers arriving on flights from South Africa.

In the Netherlands, 61 passengers from two flights arriving at Amsterdam's Schiphol Airport initially tested positive for COVID-19. Subsequent investigations identified 13 Omicron cases among these passengers, who were placed in isolation.

The rapid identification of infections across multiple countries demonstrated how international travel could facilitate the geographic spread of a newly emerging viral variant.

The spread of the omicron variant: Identification of knowledge gaps, virus  diffusion modelling, and future research needs - ScienceDirect

International Travel Restrictions and Public Health Responses

As reports of Omicron infections increased, governments introduced or strengthened travel restrictions affecting several countries in southern Africa.

Countries including Australia, New Zealand, Sri Lanka, Israel, Brazil, Canada, Iran, Japan, Thailand, and the United States adopted different measures. The European Union and the United Kingdom also introduced restrictions or additional requirements for travellers arriving from affected areas.

These measures generally aimed to reduce the importation of new infections while scientists investigated the variant's characteristics.

Depending on the country, the response included temporary flight restrictions, additional testing requirements, quarantine measures, and changes to entry conditions.

Although travel restrictions can provide additional time for public health authorities to prepare, they cannot guarantee that a variant will be prevented from entering a country. This is particularly relevant when infections may already be present in travellers who have not yet developed symptoms or received a positive test result.

International coordination, transparent reporting, and access to reliable diagnostic testing were therefore essential components of the response.

How Does Genomic Sequencing Identify New COVID-19 Variants?

Genomic sequencing is an essential surveillance technique used to identify genetic changes in viruses. It allows researchers to examine the genetic material of SARS-CoV-2 and compare different viral sequences to detect mutations and identify emerging lineages.

The process begins with the collection of a suitable clinical specimen from an infected individual. Viral genetic material is then extracted and analysed using sequencing technologies. The resulting genetic information can be compared with previously characterized SARS-CoV-2 sequences.

This approach helps scientists determine whether a sample contains a previously known viral lineage or a variant with a distinct combination of mutations.

Genomic surveillance provides several important benefits:

  • Detection of emerging variants: Identifies genetic changes that may distinguish a new lineage from previously circulating viruses.

  • Monitoring viral evolution: Helps researchers follow how SARS-CoV-2 changes over time.

  • Epidemiological investigations: Supports the analysis of transmission patterns and potential links between infections.

  • International surveillance: Allows countries to share genomic information and monitor the geographical distribution of emerging variants.

  • Scientific research: Provides genetic data that can be used to investigate the potential biological significance of viral mutations.

However, genomic sequencing is not performed on every positive COVID-19 sample. The proportion of infections that undergo sequencing varies between countries and depends on laboratory capacity, surveillance strategies, and available resources.

Consequently, the number of confirmed cases of a particular variant may represent only a fraction of the infections actually occurring in a population.

Whole-genome sequencing of SARS-CoV-2 virus in clinical isolates at a  tertiary care centre: A retrospective cross-sectional study - ScienceDirect

How Quickly Was Omicron Spreading in South Africa?

During the final weeks of November 2021, experts reported a rapid increase in COVID-19 infections in several South African provinces. This development attracted international attention because the increase occurred around the same time that Omicron was identified.

Deenan Pillay, Professor of Virology at University College London, explained that infections had increased in several provinces over a relatively short period. He also emphasized that only a proportion of positive samples underwent genomic sequencing, meaning that the actual number of Omicron infections could have been higher than the number officially confirmed.

The provinces of Gauteng, North West, and Limpopo were among the areas where health authorities were monitoring the situation closely.

The increase in detected cases raised questions about whether Omicron had a transmission advantage over previously circulating variants. However, interpreting these trends required caution because case numbers can be influenced by testing availability, population behaviour, immunity levels, and the intensity of surveillance.

At that stage, researchers needed additional epidemiological evidence to establish how much of the increase could be attributed specifically to Omicron.

What Were Scientists Investigating About Omicron?

The emergence of Omicron created several important research questions. Scientists focused on understanding the relationship between its genetic mutations and its potential effects on viral behaviour.

1. Transmissibility

Researchers investigated whether Omicron could spread more easily than earlier SARS-CoV-2 variants. The rapid increase in reported infections in South Africa suggested that the variant might have a transmission advantage, although further studies were required to establish the reasons behind this pattern.

2. Immune Evasion

The large number of mutations in the spike protein raised concerns about the possibility of reduced recognition by antibodies generated through vaccination or previous infection.

Scientists therefore began investigating whether these mutations could affect the ability of antibodies to neutralize the virus.

3. Vaccine Effectiveness

Another major question concerned the level of protection provided by existing COVID-19 vaccines against infection and severe disease caused by Omicron.

The presence of mutations did not automatically mean that vaccines would become ineffective. Laboratory studies and clinical observations were needed to evaluate how immune protection might be affected.

4. Disease Severity

Researchers also needed to determine whether Omicron infections were associated with different clinical outcomes compared with infections caused by earlier variants.

The initial reports were not sufficient to establish whether the variant caused milder or more severe disease. Reliable conclusions required larger datasets and careful assessment of clinical outcomes.

Why Continuous Monitoring of SARS-CoV-2 Variants Is Important

The emergence of Omicron demonstrated the importance of continuous genomic surveillance and international scientific collaboration.

Monitoring viral evolution enables public health authorities to detect emerging variants, assess potential epidemiological changes, and adapt diagnostic and prevention strategies when necessary.

Laboratories play a central role in this process through specimen collection, molecular testing, genetic sequencing, and the sharing of surveillance data.

Combining laboratory findings with epidemiological information allows researchers to develop a more complete understanding of how new variants emerge and spread.

The early response to Omicron also highlighted the importance of maintaining laboratory capacity, strengthening international data exchange, and ensuring that diagnostic systems can support the investigation of emerging infectious diseases.

Conclusion

The detection of the Omicron variant in the United Kingdom and several other countries in November 2021 marked an important development in the global monitoring of COVID-19.

Its identification in southern Africa, followed by reports from Europe, Asia, and other regions, prompted governments to introduce travel measures and strengthen public health surveillance.

Although the large number of mutations raised concerns about transmissibility and possible immune evasion, the scientific evidence available at the time was still developing. Researchers emphasized the importance of genomic sequencing, laboratory investigations, and epidemiological monitoring to determine the variant's actual characteristics.

The emergence of Omicron reinforced the need for effective diagnostic infrastructure, reliable specimen transportation, continuous viral surveillance, and international cooperation in responding to evolving infectious disease threats.